It represents a new potential therapeutic target, and it has recently been reported that DLL3 mRNA expression is particularly upregulated in the LCNEC subgroup with STK11/KEAP1 and TP53 co-mutations, in contrast to lower expression levels in RB1 and TP53 co-mutated LCNEC. Here, DLL3 is linked to large cell neuroendocrine carcinoma.